Kareem Jamani

Kareem Jamani

Auto-generated profile, based on publicly available information

Kareem Jamani

Division of Hematology, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2018 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
KJKareem Jamani
Kareem Jamani
LOLynn E. Onstad
Lynn E. Onstad
MBMerav Bar
Merav Bar
PCPaul A. Carpenter
Paul A. Carpenter
EKElizabeth F. Krakow
Elizabeth F. Krakow
SLStephanie J. Lee
Stephanie J. Lee
Caregivers are critical to recipient recovery after hematopoietic cell transplant (HCT); however, little is known about their long-term health and quality of life (QoL). In this study we surveyed 4446 caregiver-recipient pairs in the post-HCT period to describe their QoL and its determinants. In total, 849 caregiver-recipient pairs at a median of 6 years after autologous or allogeneic HCT responded. Among 849 responding caregivers at a median of 6 years post-HCT, 67% of caregivers were women and 68% indicated they were still providing care to the recipient. Mean and median QoL measures of caregivers were at or above general population norms; however, approximately 20% of caregivers reported poor QoL relative to general population norms. Multivariate analysis revealed that caregiver characteristics, including age, gender, and educational attainment, were important determinants of caregiver QoL. Additional determinants of caregiver QoL included recipient QoL, relapse after autologous HCT, and ongoing use of immunosuppression after allogeneic HCT. Additionally, the prevalence of depression and sleep disorders appear to be higher in caregivers than in the general population. We have identified a population of caregivers who may benefit from interventions aimed at improving QoL and health outcomes. HCT clinical practice should also consider caregiver well-being.

28 September 2023 in European Journal of Haematology
Verified
Journal Article
Closed access
RPRobert Puckrin
Robert Puckrin
KJKareem Jamani
Kareem Jamani
VJVíctor Hugo Jiménez-Zepeda
Víctor Hugo Jiménez-Zepeda

1 January 2022 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
MKMegan Kinzel
Megan Kinzel
MDMichelle Dowhan
Michelle Dowhan
AKAmit Kalra
Amit Kalra
TWTyler S. Williamson
Tyler S. Williamson
RDRosy Dabas
Rosy Dabas
JSJan Storek
Jan Storek
Post-transplant lymphoproliferative disorder (PTLD) is a potentially serious complication that occurs following hematopoietic cell transplantation (HCT), in which B cells transformed by Epstein-Barr virus (EBV) proliferate uncontrollably. It is unknown whether risk factors for the incidence of PTLD are identical to those for mortality due to PTLD, a clinically more important outcome. We sought to determine the risk factors influencing the incidence of PTLD and those influencing mortality due to PTLD in a cohort of 1184 allogenic HCT recipients. All patients were predisposed to PTLD, because their graft-versus-host disease (GVHD) prophylaxis included antithymocyte globulin. The overall PTLD incidence was 9.0%, and mortality due to PTLD was 1.1%. In multivariate analysis, risk factors for PTLD incidence include donor+/recipient- (D+/R-) EBV serostatus (subhazard ratio [SHR], 3.3; P = .002), use of a donor other than an HLA-matched sibling donor (non-MSD) (SHR, 1.7; P = .029), receipt of total body irradiation (TBI; SHR, 3.3; P = .008), and the absence of GVHD (SHR, 3.3; P < .001). The sole risk factor for mortality due to PTLD among all patients was D+/R- serostatus (SHR, 5.8; P = .022). Risk factors for mortality due to PTLD among patients who developed PTLD were use of a bone marrow (BM) graft (compared with peripheral blood stem cells [PBSCs]; SHR, 22.8; P < .001) and extralymphatic involvement (SHR, 14.6; P < .001). Interestingly, whereas the absence of GVHD was a risk factor for PTLD incidence, there was a trend toward the presence of GVHD as a risk factor for PTLD mortality (SHR, 4.2; P = .093). Likewise, whereas use of a BM graft was a risk factor for PTLD mortality, there was a trend toward use of a PBSC graft as a risk factor for PTLD incidence (SHR, 0.44; P = .179). Some risk factors for the incidence of PTLD are identical to the risk factors for mortality due to PTLD (ie, D+/R- serostatus), whereas other risk factors are disparate. Specifically, TBI was identified as a risk factor for PTLD incidence but not for PTLD mortality; the absence of GVHD was a risk factor for PTLD incidence, whereas the presence of GVHD was possibly a risk factor for PTLD mortality; and receipt of a PBSC graft was possibly a risk factor for PTLD incidence, whereas receipt of a BM graft was a risk factor for PTLD mortality.

30 November 2016 in Blood Advances
Verified
Journal Article
Open access
PDF file
KJKareem Jamani
Kareem Jamani
JMJudy MacDonald
Judy MacDonald
MLMartin Lavoie
Martin Lavoie
TWTyler S. Williamson
Tyler S. Williamson
CBChristopher B. Brown
Christopher B. Brown
JSJan Storek
Jan Storek
Key Points: Two years of antiviral prophylaxis and VZV vaccination reduce the incidence of VZV disease and nearly eliminate post–herpetic neuralgia.

1 December 2021 in Leukemia Research
Verified
Journal Article
Closed access
CMChen-En Ma
Chen-En Ma
SGSunita Ghosh
Sunita Ghosh
CLCatherine Leyshon
Catherine Leyshon
NBNikki Blosser
Nikki Blosser
DDDeonne Dersch-Mills
Deonne Dersch-Mills
KJKareem Jamani
Kareem Jamani

29 October 2021 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
RPRachel Phelan
Rachel Phelan
AIAnnie Pearl Im
Annie Pearl Im
RHRebecca L. Hunter
Rebecca L. Hunter
YIYOSHIHIRO INAMOTO
YOSHIHIRO INAMOTO
MLMaria Teresa Lupo-Stanghellini
Maria Teresa Lupo-Stanghellini
ATAndré Tichelli
André Tichelli
Male-specific late effects after hematopoietic cell transplantation (HCT) include genital chronic graft-versus-host disease (GvHD), hypogonadism, sexual dysfunction, infertility, and subsequent malignancies, such as prostate, penile, and testicular cancer. They may be closely intertwined and cause prolonged morbidity and decreased quality of life after HCT. Here, we provide a systematic review of male-specific late effects in a collaboration between transplant physicians, endocrinologists, urologists, dermatologists, and sexual health professionals through the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research, and the Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. We utilized systematic review methodology to summarize incidence, risk factors, screening, prevention and treatment of these complications and provide consensus evidence-based recommendations for clinical practice and future research. Most of the evidence regarding male GvHD is still based on limited data, precluding strong therapeutic recommendations. We therefore recommend to systematically screen for male genital GvHD regularly and report it to large registries to allow for a better understanding. Future research should also address treatment since little published evidence is available to date. Male-specific endocrine consequences of HCT include hypogonadism which may also affect bone health. Since the evidence is scarce, current recommendations for hormone substitution and/or bone health treatment are based on similar principles as for the general population. Following HCT, sexual health decreases and this topic should be addressed at regular intervals. Future studies should focus on interventional strategies to address sexual dysfunction. Infertility remains prevalent in patients having undergone myeloablative conditioning, which warrants offering sperm preservation in all HCT candidates. Most studies on fertility rely on descriptive registry analysis and surveys, hence the importance of reporting post-HCT conception data to large registries. Although the quality of evidence is low, the development of cancer in male genital organs does not seem more prevalent than in the general population; however, subsequent malignancies in general seem to be more prevalent in males than females, and special attention should be given to skin and oral mucosa. Male-specific late effects, probably more under-reported than female-specific complications, should be systematically considered during the regular follow-up visits of male survivors who have undergone HCT. Care of patients with male-specific late effects warrants close collaboration between transplant physicians and specialists from other involved disciplines. Future research should be directed towards better data collection on male-specific late effects and on studies about the interrelationship between these late effects, to allow the development of evidence based effective management practices.